Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10053021 | 0.88 | AGTR1 (0.55) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL3630129 | 0.88 | AGTR1 (0.53) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL17653793 | 0.88 | AGTR1 (0.54) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6891884 | 0.88 | AGTR1 (0.56) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL13755335 | 0.86 | AGTR1 (0.58) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL1237602 | 0.86 | AGTR1 (0.57) | AGTR1AGTR2 | |
| SCHEMBL10021557 | 0.86 | AGTR1 (0.53) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL8791077 | 0.85 | AGTR1 (0.52) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL60 | 0.85 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 0.85 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105017226-A | Trityl Losartan synthesis method | CHEER FINE PHARMACEUTICAL ANHUI CO LTD | 2015-11-04 | — | — | CN | claimed |
| CN-103965171-A | Preparation method for Allisartan Isoproxil | ALLIST PHARMACEUTICALS INC | 2014-08-06 | — | — | CN | claimed |
| CN-102711735-A | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases | GP PHARM SA | 2012-10-03 | — | — | CN | claimed |
| US-20090076281-A1 | PROCESS FOR THE PREPARATION OF LOSARTAN AND ITS SALTS | MEDICHEM, S.A. (ES) | 2009-03-19 | — | — | US | claimed |
| US-7345071-B2 | Process for the synthesis of Losartan potassium | IPCA LABORATORIES LIMITED (IN) | 2008-03-18 | — | — | US | claimed |
| EP-1891055-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | Medichem, S.A. (ES) | 2008-02-27 | — | — | EP | claimed |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | CADILA PHARMACEUTICALS LTD. (IN) | 2007-10-25 | — | — | US | claimed |
| WO-2007020533-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM | MEDICHEM, S.A. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060287537-A1 | Method of removing the triphenylmethane protecting group | ZENTIVA, A.S. (CZ) | 2006-12-21 | — | — | US | claimed |
| EP-1709034-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF LOSARTAN POTASSIUM | IPCA Laboratories Limited (IN) | 2006-10-11 | — | — | EP | claimed |
| US-20060020005-A1 | Process for preparing losartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1608641-A1 | A PROCESS FOR THE SYNTHESIS OF LOSARTAN POTASSIUM | IPCA Laboratories Limited (IN) | 2005-12-28 | — | — | EP | claimed |
| WO-2005066158-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF LOSARTAN POTASSIUM | IPCA LABORATORIES LIMITED (IN) | 2005-07-21 | — | — | WO | claimed |
| US-6916935-B2 | Losartan potassium synthesis | IPCA LABORATORIES (IN) | 2005-07-12 | — | — | US | claimed |
| US-20050070586-A1 | Process for the synthesis of losartan potassium | IPCA LABORATORIES LIMITED (IN) | 2005-03-31 | — | — | US | claimed |
| WO-2005023758-A2 | PROCESS FOR THE PREPARATION OF LOSARTAN POTASSIUM FORM I | KHAMAR BAKULESH MAFATLAL (IN) | 2005-03-17 | — | — | WO | claimed |
| WO-2005021535-A2 | A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP | ZENTIVA, A.S. (CZ) | 2005-03-10 | — | — | WO | claimed |
| US-20040224998-A1 | Losartan potassium synthesis | IPCA LABORATORIES, LTD. (IN) | 2004-11-11 | — | — | US | claimed |
| WO-2004087691-A1 | A PROCESS FOR THE SYNTHESIS OF LOSARTAN POTASSIUM | IPCA LABORATORIES LIMITED (IN) | 2004-10-14 | — | — | WO | claimed |
| US-20040097568-A1 | Crystalline form of losartan potassium | DR. REDDY'S LABORATORIES LIMITED | 2004-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097568-A1 | Crystalline form of losartan potassium | REN, AGT, AGTR1 | AGTR1 3/4885AGTR2 5/4885ABCC4 1987/4885 |
| US-20060287537-A1 | Method of removing the triphenylmethane protecting group | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885ABCC4 3624/4885 |
| US-20070249839-A1 | Process for the Preparation of Losartan Potassium Form I | AGTR1, REN, AGT | AGTR1 1/4885AGTR2 4/4885ABCC4 2414/4885 |
| US-20050070586-A1 | Process for the synthesis of losartan potassium | ADH1C, KCNN3, AGTR1 | AGTR1 3/4885AGTR2 13/4885ABCC4 3985/4885 |
| US-20060020005-A1 | Process for preparing losartan | AGTR1, AGT, REN | AGTR1 1/4885AGTR2 4/4885ABCC4 3814/4885 |
| US-20040224998-A1 | Losartan potassium synthesis | ADH1A, AGTR1, ADH1C | AGTR1 2/4885AGTR2 12/4885ABCC4 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.